Skip to main content

Memory Care Costs in Wichita, KS — What You Can Expect to Pay

Cost & Pricing Benchmark · US

Cost & Financial Benchmark

Grounded against 7 primary statutory & directory sources.Markdown / Cite ↗

Memory Care Costs in Wichita, KS — What You Can Expect to Pay — Cost & Financial Benchmark

Key Takeaways

Memory care in Wichita, KS typically starts around $5,975/month baseline (KS assisted living median, CareScout Cost of Care Survey 2025). Compare local providers, Medicaid options, and reviews.

Cost Overview

Service Min Max Unit
Memory Care$5,975$5,975per month

CareScout Cost of Care Survey 2025 (KS assisted living baseline). Actual rates in Wichita may vary.

Memory Care Costs in Wichita, KS

If you're researching memory care costs in Wichita, you're navigating one of the most stressful decisions a family can face — often under time pressure after a fall, a hospital stay, or a sudden decline. With 161 providers in the area, costs vary significantly based on the level of care, the provider's qualifications, and whether you need part-time or round-the-clock support.

A common and costly surprise: Medicare does not cover long-term memory care. It only covers short-term skilled nursing (up to 100 days) after a qualifying hospital stay.[1] For ongoing care, families typically rely on Medicaid (if eligible — and there are often waiting lists), VA benefits, long-term care insurance, or out-of-pocket savings.[1]

Below, we break down what memory care actually costs in Wichita, what's typically included in the price, the hidden fees to watch for, and how families pay for it.

Help Other Families

Have you or a loved one paid for Memory Care in Wichita? Share your experience to help us build a more transparent market.

Medicare Quality Ratings in Wichita

Of the 51 Medicare-certified facilities in Wichita, 45% are rated 4 or 5 stars.

  • 5 Stars: 7
  • 4 Stars: 16
  • 3 Stars: 12
  • 2 Stars: 10
  • 1 Stars: 6

Compare facilities on Medicare Care Compare.

Hidden Fees to Ask About

The advertised monthly rate rarely tells the full story. Before signing any agreement, ask about these common additional charges:

  • Care level assessments — Many facilities assess your care needs after you sign the lease, then add $500–$2,000/month based on the assessment tier.
  • Medication management — Each medication administered can cost $50–$200/month extra. If your loved one takes 8+ medications, this adds up fast.
  • Incontinence supplies — Often billed separately at $100–$300/month, even in facilities that include "personal care."
  • Laundry service — $50–$100/month in many communities, sometimes only for personal items.
  • Transportation — Rides to medical appointments may cost $25–$75 per trip.
  • Community fee — A one-time move-in fee of $1,000–$5,000 that is often non-refundable.

Critical question: Ask what happens if your loved one’s savings run out. Some facilities will help transition to Medicaid; others require you to leave within 30 days.

Funding Your Care

Care costs can feel daunting, but there are several routes that may help reduce what you pay out of pocket.

  • Medicare — Covers short-term skilled nursing care and limited home health services following a qualifying hospital stay. Does not cover long-term custodial care.
  • Medicaid — For those who qualify financially, Medicaid covers nursing home care and, in many states, home and community-based services through waiver programs. Eligibility and benefits vary by state.
  • VA Benefits — Veterans and surviving spouses may qualify for Aid and Attendance, which provides a monthly pension supplement to help cover care costs.
  • Long-term care insurance — Private policies purchased before the need arises can cover a range of care settings. Review your policy carefully for benefit triggers, daily limits, and elimination periods.

Your Medicare Plan’s Star Rating May Be a Mirage This Year — 3 Things to Check Before Open Enrollment

The window: Medicare Open Enrollment runs October 15 – December 7, 2026, and changes take effect January 1, 2027. This is the one annual window most people have to switch Medicare Advantage or Part D prescription drug plans for 2027.

What actually changed in the ratings formula: CMS’s Contract Year 2027 final rule removed 11 Star Ratings measures — mostly administrative metrics such as call-center performance (including interpreter and TTY availability) and appeals handling — and reinstated the general reward factor in place of the Health Equity Index (HEI). Because fewer operational metrics can pull a composite score down, a plan can show a higher star rating this year without its care having improved at all. CMS’s own regulatory analysis projects roughly $18.5B ($18.56 billion) flowing to plan sponsors over 10 years from these formula and bonus-payment changes. Only one genuinely new clinical measure was added for the 2027 measurement year: depression screening and follow-up.

What families should do — read under the headline star: Check the underlying categories (drug coverage, care coordination, and member experience with the care itself), then verify the three things that actually determine whether a plan works for your parent in 2027:

  1. Their medications are on the plan’s 2027 formulary at a tolerable tier — confirm every routine prescription, tier placement, and any prior-authorization or step-therapy rules (alongside the finalized 2027 Part D $700 maximum deductible and $2,400 annual out-of-pocket cap).
  2. Their doctors and hospital are in network for 2027 — provider networks change yearly, so check each primary care physician, specialist, and hospital by name in the plan’s 2027 directory.
  3. Their pharmacy is preferred in-network — copays at a standard in-network pharmacy can be substantially higher than at a preferred in-network pharmacy under the same plan.

Check stars last, not first. A high-starred plan that drops your parent’s specialist or moves a daily medication to a non-preferred tier will cost your family far more than a lower-starred plan that covers their actual doctors and prescriptions.

Watch for the marketing surge: Federal broker and agent marketing restrictions were loosened effective October 1, 2026, so families should expect a higher volume of calls, mailers, and ads this season — and should know that a sales call is not advice. For free, unbiased guidance with no sales commission, contact your local State Health Insurance Assistance Program (SHIP) counselor, and review our live Medicare Open Enrollment 2026 key dates explainer, 2027 plan-ending checklist, 2027 Medicare costs guide, and FAQ entry (“When is Medicare Open Enrollment for 2026?”) for the dates and plan-ending rules.

Sources & 2027 rule-change explainers: CMS Contract Year 2027 Medicare Advantage and Part D Final Rule Fact Sheet; Medicare Star Ratings 2027 Rule-Change Explainer (Avidon Health, updated 2026-10-03); and 2027 Star Ratings Measure-Set & Reward-Factor Analysis (RISE Health, updated 2026-10-03).

What to Expect

Memory care facilities specialize in supporting people with Alzheimer's disease and other forms of dementia, with secured environments and staff trained in cognitive care techniques.

Cannabis Oil Cut Late-Stage Dementia Agitation in 87% of Patients — What Families Should Know Before Asking Their Doctor

The burden of late-stage agitation: Agitation — pacing, vocal outbursts, restlessness, and acute physical distress — affects roughly half of late-stage dementia patients and is one of the most distressing symptoms families deal with. More than a third of patients keep experiencing severe agitation despite standard prescriptions such as benzodiazepines, opioids, or antipsychotics, all of which carry significant risks of their own in older adults with dementia, including heavy sedation, falls, and FDA boxed warnings.

What the LiBBY trial actually was: LiBBY (Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol) was an NIH-funded Phase 2 randomized, double-blind, placebo-controlled trial of 120 participants, all hospice-eligible with advanced dementia and clinically significant agitation. Participants received a standardized oral combination of 2 mg THC / 100 mg CBD twice daily for 12 weeks (dissolved in digestible oil) or placebo; results were presented at AAIC 2026 (London).

What it found — and the honest safety picture: At week 12, 87.2% of treated patients were rated improved on clinician global impression vs. 23.6% on placebo; the benefit appeared fast (a 6.27-point greater reduction on the CMAI agitation scale at week 2, p=0.0004) and held through week 12 (p<0.0001). Stated plainly alongside that benefit, overall adverse-event rates were similar to placebo (46.7% vs. 42.4%), but serious adverse events were higher in the treatment arm (23.3% vs. 11.9%), and deaths were 13.1% vs. 5.1% with no specific cause pattern — numbers that must be read in the context of an end-of-life population, and that families deserve to see unspun.

What to ask the doctor:

  • Is agitation like my parent’s the kind this trial studied? (LiBBY studied hospice-eligible, late-stage dementia patients with clinically significant agitation — not earlier-stage wandering or mild sundowning.)
  • What have we already tried, and what did it cost them? Review non-drug comfort measures and current medications, including whether sedatives or antipsychotics are causing side effects without relieving distress.
  • If we were interested, what would the legal and hospice-policy position be in our state and with our hospice? State laws, facility licensing rules, and hospice protocols vary widely.
  • What interactions with current sedatives or opioids would we watch for? Oral THC and CBD can amplify sedation, dizziness, and drug levels when combined with benzodiazepines, opioids, or antipsychotics.
  • What would we monitor, and when would we stop? Agree in advance on specific target symptoms, side-effect warning signs, and a clear stopping rule.

Essential caveats for families: This evidence comes from a single Phase 2 trial in a hospice-eligible end-of-life population only; the studied oral THC/CBD formulation is not a prescription option today; there is no long-term data beyond the 12-week trial; and the legal status of THC/CBD products varies by state. Commercial dispensary or over-the-counter CBD/THC products are not equivalent to a standardized clinical-trial formulation, and nothing in this section is a recommendation to obtain or use cannabis products.

Sources: Psychiatric Times: Oral Cannabinoid From MediPharm Shows Significant Reduction in Agitation in Alzheimer Disease and Dementia (2026-10-03); and The Educated Patient: A CBD/THC Combination Reduced Dementia Agitation in Nearly 9 in 10 Patients (2026-10-04).

Finding Regulated Providers

Memory Care providers are regulated by State licensing boards. Before choosing a provider in Wichita, check their latest quality rating and inspection reports. You can also browse and compare providers on families.care.

Find care providers in Wichita, KS

Browse profiles, compare ratings, and connect with local providers.

Search Providers →

Not sure where to start?

Answer a few questions and get personalised care recommendations.

Not sure where to start →

Verified references & primary sources

7 verified sources

Quantitative and regulatory claims in this guide are grounded against official registries and benchmark datasets.

  1. Statutory Registry
    CareScout · Verified 2026-08-15 · General senior-care planning information.

    “A common and costly surprise: Medicare does not cover long-term memory care.”

  2. Statutory Registry
    Medicare.gov · Verified 2026-08-15 · General senior-care planning information.

    “Compare facilities on Medicare Care Compare .”

  3. Statutory Registry
    Medicaid.gov · Verified 2026-07-10 · General senior-care planning information.
  4. Statutory Registry
    National Institute on Aging · Verified 2026-07-10 · General senior-care planning information.
  5. Statutory Registry
    U.S. Department of Veterans Affairs · Verified 2026-08-15 · General senior-care planning information.
  6. World Bank · Verified 2026-08-07 · National health spending, share of population aged 65+, consumer-price inflation, GDP per capita, old-age dependency ratio, and government share of health spending.
  7. International Monetary Fund · Verified 2026-08-07 · Consumer-price inflation forecast for the current year.

How we research and verify this information

Our team compiles this listing from public records and provider data, and reviews it against authoritative sources. Read our editorial standards and research methodology.

  • Cost of Care Survey (2025)Publisher: CareScout. Supports: General public-program and care-cost context; not a local price quote. Last checked: 2026-08-15.
  • Skilled nursing facility coveragePublisher: Medicare.gov. Supports: General public-program and care-cost context; not a local price quote. Last checked: 2026-08-15.
  • Medicaid coverage and eligibilityPublisher: Medicaid.gov. Supports: General public-program and care-cost context; not a local price quote. Last checked: 2026-07-10.
  • Long-term-care guidance for familiesPublisher: National Institute on Aging. Supports: General public-program and care-cost context; not a local price quote. Last checked: 2026-07-10.
  • VA pension rates (Aid & Attendance)Publisher: U.S. Department of Veterans Affairs. Supports: General public-program and care-cost context; not a local price quote. Last checked: 2026-08-15.